What Happened

A 65-year-old pharmacy owner and two Celina, Tennessee pharmacies he majority-owned agreed to pay $450,000 and accept a permanent ban on handling controlled substances under a consent judgment announced August 10, 2026 by the U.S. Attorney's Office for the Middle District of Tennessee.

The resolution covers Oakley Pharmacy, Inc., doing business as Dale Hollow Pharmacy, and Xpress Pharmacy of Clay County LLC, along with their majority owner. The consent judgment and permanent injunction resolve civil claims brought by the United States under the Controlled Substances Act and the False Claims Act.

Under the terms of the settlement, the pharmacies and owner are permanently barred from handling controlled substances — effectively ending their ability to dispense DEA-regulated medications — and agreed to pay $450,000 to resolve the government's claims.

What Went Wrong

This is a pharmacy-level enforcement outcome, and the severity of the remedy says more than the dollar amount. A permanent ban on handling controlled substances is one of the most consequential penalties available in a civil CSA case — it removes the registrant from the regulated pharmaceutical supply chain entirely. Several control failures typically underlie this kind of result:

  • Diversion-control breakdowns at the owner level. The claims reached the majority owner as well as the pharmacy entities, signaling that responsibility for controlled substance oversight was not effectively discharged at the top of the organization.
  • Federal program exposure. The False Claims Act component indicates the alleged conduct also implicated billing to federal health care programs, compounding the CSA exposure with fraud-based liability.
  • Missing legitimate-purpose safeguards. Cases that end in a permanent CS ban frequently involve dispensing that strayed from a legitimate medical purpose — prescriptions filled without adequate verification of the prescriber, the patient, or the clinical need.
  • Recordkeeping and accountability gaps. CSA registrants are required to maintain complete and accurate records that demonstrate every controlled substance can be traced from receipt to dispensing. Failure to do so is itself a violation and makes diversion harder to detect.

How It Could Have Been Prevented

  • Maintain a documented pharmacy compliance program with clear lines of responsibility for controlled substance oversight, including designated pharmacist-in-charge duties and owner-level accountability.
  • Verify a legitimate medical purpose for every controlled substance prescription — confirm prescriber credentials, patient identity, and clinical indication before dispensing, and document the review.
  • Reconcile controlled substance inventory on a regular basis against purchase and dispensing records, and investigate discrepancies immediately rather than carrying them forward.
  • Screen staff — including pharmacists, technicians, and delivery personnel — through background checks, and restrict system access to those with a job-related need.
  • Treat federal program billing as part of the compliance program: claims for controlled substances should be auditable against the prescription record, the inventory record, and the legitimate-purpose documentation.
  • Respond to DEA inspections, audit findings, or suspicious-order notices with a formal corrective action plan — documented, timed, and verified — rather than waiting for civil enforcement.

Related Guidance

Sources